IFNA2 and acute myeloid leukemia: The combination of IFNα with the histone deacetylase inhibitor valproic acid (VPA) has been reported to be synergistic in several solid cancer models (Jones et al. 2009; Iwahashi et al. 2011; Hudak et al. 2012), suggesting that this combination could represent a valuable novel therapeutic strategy in AML.